Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting

- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling seizure reduction in participants without MTS during the 4-6-month interim period (N=3) - BILATERAL MTLE: Low dose resulted in 64% median disabling seizure reduction during the 4-6-month interim period (N=4) - DURABILITY: Participants have maintained reductions in seizure frequency past the 12-month primary endpoint - SAFETY: Cell therapy continues to be well-tolerated, with no serious adverse events attributed to the cells or administration procedure - COGNITION: No substantial group decline s in cognitive performance detected in any cohort - PIVOTAL TRIAL: Enrollment of first patient in EPIC Phase 3 trial of low-dose rezanecel in drug-resistant MTLE planned for 2H 2026 - REGULATORY: WHO/INN Programme recommended rezanecel as the non-proprietary name of NRTX-1001 SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company developing regenerative cell therapies for epilepsy and other disorders of the nervous system, today presented new clinical results from its ongoing open-label Phase 1/2 trials evaluating rezanecel (NRTX-1001), a one-time, allogeneic interneuron cell therapy, for drug-resistant mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS). The data were presented at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place in Chicago and online, April 18-22. The updates included data from participants enrolled in two Phase 1/2 clinical trials evaluating rezanecel in drug refractory unilateral or bilateral MTLE, with or without MTS. A total of 31 participants have been dosed across both studies with either a low or a high dose of rezanecel. Importantly, data were presented on 15 participants followed for more than 18 months after single-dose administration, providing the most mature assessment to date of rezanecel durability, safety, and quality-of-life outcomes. Neurona's upcoming Phase 3 EPIC (EPIlepsy Cell therapy) study design was also presented. "We are delighted to share the ... Full story available on Benzinga.com